

<教科書>

**Book**

1. Hirakawa A, **Sato H**, Daimon T, Matsui S. *Modern Dose-Finding Designs for Cancer Phase I Trials: Drug Combinations and Molecularly Targeted*, 2018. Springer.

**Book chapter**

2. **Sato H**, Yamaguchi T, Ando Y, Nonaka T. The Evolution of the Drug Evaluation Process in Japan. In *Oncology Clinical Trials Successful Design, Conduct, and Analysis, Second Edition*, 2018, Springer Publishing Company.
3. Hirakawa A, **Sato H**. A comparative study of model-based dose-finding methods for two-agent combination trials. In *Frontiers of Biostatistical Methods and Applications in Clinical Oncology*, 2017, Springer.

**翻訳**

4. 平川晃弘 (監訳). 浅野淳一, 上村鋼平, **佐藤宏征**, 木下文恵, 武内亜希子 (共訳). 臨床試験のためのデータモニタリング委員会: 実践ハンドブック. スーザン・エレンバーク, トーマス・フレミング, デビット・デメッツ. *Data Monitoring Committees in Clinical Trials: A Practical Perspective*. 2017. サイエンティスト社.

<査読付論文>

**Biostatistics and Data Science**

1. Hirakawa A, **Sato H**, Hanazawa R, Suzuki K; Japanese Alzheimer's Disease Neuroimaging Initiative. Estimating the longitudinal trajectory of cognitive function measurement using short-term data with different disease stages: Application in Alzheimer's disease. *Statistics in Medicine*. 2022. doi: 10.1002/sim.9504.
2. Hirakawa A, **Sato H**, Igeta M, et al. Regulatory issues and the potential use of Bayesian approaches for early drug approval systems in Japan. *Pharmaceutical Statistics*, 2022; 21:691-695.
3. Hirakawa A, Asano J, **Sato H**, Teramukai S. Master protocol trials in oncology: Review and new trial designs. *Contemporary Clinical Trial Communications*, 2018; 12: 1-8.
4. **Sato H**, Hirakawa A (co-first author), Hamada C. An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials. *Statistics in Medicine*, 2016; 35: 4093-4109.
5. Hirakawa A, **Sato H**. Authors' Reply: Response to Letter to the Editor by Drs Riviere et al.

6. *Statistics in Medicine*, 2016; 35: 479-480.
7. Hirakawa A, **Sato H**, Gosho M. Effect of design specifications in dose-finding trials for combination therapies in oncology. *Pharmaceutical Statistics*, 2016; 15: 531-540.
8. Hirakawa A, **Sato H**. Authors' Reply: Response to Letter to the Editor by Drs Riviere et al. *Statistics in Medicine*, 2016; 35: 479-480.
9. Hirakawa A, Wages NA, **Sato H**, Matsui S. A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies. *Statistics in Medicine*, 2015; 34: 3194-3213.

### **Cooperative Clinical and Basic Researches**

10. Murata K, Takahashi Y, Inaba O, Nitta J, Kobori A, Sakamoto Y, Nagata Y, Tanimoto K, Matsuo S, Yamane T, Morita N, Satomi K, **Sato H**, Hanazawa R, Hirakawa A, Goya M, Sasano T. Efficacy of Left Atrial Posterior Wall Isolation Guided by Lesion Size Prediction Module for Nonparoxysmal Atrial Fibrillation. *EP Europace*, 2022. doi:10.1093/europace/euac079.
11. Nakayama K, Shachar S, Finn E H, **Sato H**, Hirakawa A, Misteli T. Large-scale mapping of positional changes of hypoxia-responsive genes upon activation. *Molecular Biology of the Cell*, 2022; **33**: ar72.
12. Takino K, Kameshima M, Asai C, Kawamura I, Tomita S, **Sato H**, Hirakawa A, Yamada S. Neuromuscular electrical stimulation after cardiovascular surgery mitigates muscle weakness in older individuals with diabetes. *Ann Phys Rehabil Med*, 2022; 7: 101659.
13. Takahashi Y, Nitta J, Kobori A, Sakamoto Y, Nagata Y, Tanimoto K, Matsuo S, Yamane T, Morita N, Satomi K, Inaba O, Murata K, Sasaki Y, Yoshimoto D, Kaneko M, Tanimoto Y, Isogai R, Yamashita S, **Sato H**, Hanazawa R, Hirakawa A, Goya M, Sasano T. Alcohol Consumption Reduction and Clinical Outcomes of Catheter Ablation for Atrial Fibrillation. *Circ Arrhythm Electrophysiol*. 2021; **14**: e009770.
14. Ikenouchi T, Inaba O, Takamiya T, Inamura Y, Sato A, Matsumura Y, **Sato H**, Hirakawa A, Takahashi Y, Goya M, Sasano T, Nitta J. The impact of left atrium size on selection of the pulmonary vein isolation method for atrial fibrillation: Cryoballoon or radiofrequency catheter ablation. *American Heart Journal*, 2021; **231**: 82-92.
15. Kato M, Hirakawa A, **Sato H**, Hanazawa R, Naito Y, Tochigi K, Sano T, Ishida S, Funahashi Y, Fujita T, Matsukawa Y, Hattori R, Tsuzuki T. Grade group 2 (10%  $\geq$  GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate. *International Journal of Clinical Oncology*, 2021; **26**: 764-769.
16. Nagai S, Urata M, **Sato H**, Mikami M, Kuga W, Yanagihara R, Miyamoto D, Suzuki Y, Shikano M. Evolving Japanese regulations on companion diagnostics. *Nature Biotechnology*, 2016; **34**: 141-144.

## <査読付論文>

### Review

1. 平川晃弘, 浅野淳一, 佐藤宏征, 橋本大哉, 手良向聡. がん臨床試験におけるベイズ流バスケットデザインの理論と実装. *計量生物学*, 2019; 39: 103-122.
2. 平川晃弘, 浅野淳一, 佐藤宏征, 手良向聡. マスタープロトコルに基づくがん臨床試験. *計量生物学*, 2019; 39: 85-101.

### Regulatory Science

3. 平川晃弘, 佐藤宏征, 井桁 正堯, 藤川 桂, 堀口 剛, 大門 貴志, 手良向 聡. 希少疾患領域の治験におけるベイズ流アプローチの利用可能性と留意事項. *薬理と治療 Jpn Pharmacol Ther* 2021; 49(s1): s72-79.

### Cooperative Clinical and Basic Researches

4. 平川晃弘, 佐藤宏征. 生存時間解析. *Journal of Clinical Rehabilitation*, 30: 977-981, 2021

## <国際学会発表（口頭発表）>

1. Sato H, Sasaki M, Hirakawa A. Model calibration approaches for model uncertainty of dose-efficacy relationship in phase I trials for monotherapy of molecularly targeted agents. 2022 WNAR/IMS/JR Annual Meeting, Jun 10-15, 2022, Virtual conference. Invited session.
2. Sato H, Asano J, Ando Y. Consideration of the estimation method for regional treatment effects in multi-regional clinical trials—regulatory perspectives—. International Symposium on Biopharmaceutical Statistics, Aug 26-30, 2019, Kyoto International Conference Center, Kyoto, Japan.
3. Sato H. Regulatory Japanese experience on adaptive clinical trial designs. Austria-Japan Joint Statistics Workshop Mar 23-24, 2015, Osaka University Nakanoshima Center, Osaka, Japan.
4. Sato H. Statistical issues in evaluating MRCT – Experiences in Japan. ISBS/DIA Joint Statistical Conference 2015, Jun 29 - Jul 1, 2015, Beijing Marriott Hotel City Wall, Beijing, China.
5. Sato H, Hirakawa A, Hamada C. An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials. East Asia Regional Biometric Conference 2015. Dec 20-22, 2015, Kyushu University, Fukuoka, Japan.

## <国際学会（ポスター発表）>

1. Sato H, Hirakawa A, Hamada C. Dose-finding approach based on efficacy and toxicity outcomes

in phase I oncology trials for Molecularly Targeted Agents. Eastern North American region (International Biometric Society) 2015 Spring meeting, Mar 15-18, 2015, Hyatt Regency Miami, Miami, FL, USA.

<国内学会（口頭発表）>

1. 佐藤宏征. Regulatory Perspectives (セッション名：Changing Landscape of Phase 1 Trials in Oncology). 第14回DIA日本年会, 2017年11月12-14日, 東京ビッグサイト, 有明 (東京).
2. 佐藤宏征, 平川晃弘, 浜田知久馬. がん分子標的薬の用量探索法. 日本計算機統計学会第31回大会, 2017年5月11日-12日, 森戸記念館, 神楽坂 (東京).
3. 佐藤宏征, 平川晃弘, 浜田知久馬. がん分子標的薬の用量探索法. 2017年日本計量生物学会年会, 2017年3月16日-17日, 中央大学後楽園キャンパス, 後楽園 (東京).
4. 佐藤宏征. 個別化医療に関わる医薬品開発のための臨床試験デザインについて—審査及び治験相談の経験を踏まえ—. 日本計算機統計学会第30回シンポジウム, 2016年11月24日-25日, プラザヴェルデ, 沼津 (静岡).
5. 佐藤宏征. 臨床研究における統計家の役割：規制当局において. 第36回日本臨床薬理学会総会, 2015年12月9日-11日, 京王プラザホテル, 新宿 (東京).
6. 佐藤宏征. Recent Advances in Clinical Trial Design for Personalized Medicine – Regulatory Perspective. 第12回DIA日本年会, 2015年11月15日-17日, 東京ビッグサイト, 有明 (東京).
7. 佐藤宏征. A Regulatory Perspective on the Use of Adaptive Design in Drug Development. 第11回DIA日本年会, 2014年11月16日-18日, 東京ビッグサイト, 有明 (東京).

<競争的資金>

研究代表者

1. 日本学術振興会 科学研究費 研究活動スタート支援. 研究課題名：ベイズ流モデル平均化を応用した新規ベイズ流用量探索法の研究開発. (研究代表者). 2020 (R2) 年度～2021 (R3) 年度.